OverviewZogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
NASDAQ | ZGNX (Common Stock)
$14.40 + 1.35
Data as of 09/22/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Investor Events More
Tuesday, August 8, 2017 4:30 p.m. ET
Q2 2017 Zogenix, Inc. Earnings Conference Call
Wednesday, June 7, 2017 2:00 p.m. ET
Zogenix, Inc. at the Jefferies 2017 Global Healthcare Conference